Eris margin slips as expenses outpace revenue growth
Operating margin fell 1.88 percentage points YoY, while a lower tax rate helped net profit grow faster than pre-tax profit.
Filed 29 Jul 2026, 13:10 IST · ERIS Lifesciences Ltd (ERIS)
Key takeaways
- Consolidated revenue grew +12.97% YoY, but expenses grew faster at +16.27%, taking operating margin down 1.88 percentage points to 33.92%.
- Net profit rose +14.56% YoY as the tax rate fell 2.20 percentage points, while other income contributed only 1.11% of pre-tax profit.
- The company remained 4.09 percentage points above the 29.83% median operating margin of 11 reporting healthcare peers.
Price around the results
Revenue momentum returns, but costs absorb more of the growth
Consolidated revenue grew +12.97% YoY and +15.42% QoQ, but expenses rose faster at +16.27% YoY and +19.47% QoQ. That cost gap limited operating-profit growth to +7.05% YoY and pushed operating margin down 1.88 percentage points YoY to 33.92%. QoQ margin also narrowed 2.24 percentage points after Q4FY26's 36.16%.
Lower tax rate lifts profit conversion; other income is not a support
Net profit grew +14.56% YoY, ahead of the +11.42% increase in pre-tax profit, as the tax rate declined 2.20 percentage points to 20.15%. The QoQ comparison is distorted by Q4FY26's negative 75.08% tax rate and Rs 279.10 cr net profit, which reflected a tax benefit. Other income was just 1.11% of pre-tax profit, so reported profit was not materially dependent on non-operating income; interest expense also fell 4.17% YoY.
Margin remains above peers but has not regained its recent peak
Eris's 33.92% operating margin was 4.09 percentage points above the 29.83% median for 11 healthcare peers that had reported the quarter. The quarterly trend is uneven rather than a straight decline: margin rose to 36.37% in Q2FY26, fell to 34.88% in Q3FY26, recovered to 36.16% in Q4FY26, and then declined in Q1FY27. The YoY comparison is cleaner for this quarter and shows the margin below the 35.80% recorded in Q1FY26.
Management points to OAD execution and a longer insulin pipeline
Management said it aims to take the oral anti-diabetic segment to 70% of market growth over the next two quarters of FY27. It also said Sundae posted its first full quarter with Rs 12 cr of sales in an Rs 88 cr generic semaglutide market, while retaining the number-one position in prescription and sale-unit share in June 2026. Management said its five-product insulin pipeline is scheduled to start launching from FY28, even as the represented RHI and Glargine market was declining 1.2% YoY.
Past result-day moves have been evenly split
The stock rose after four of the past eight results and fell after four, with a median absolute move of 3.76%. The historical record therefore points to a mixed reaction rather than a consistent direction; the current filing does not yet have a reported result-day move.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹873 cr | ₹757 cr | +15.42% | +12.97% |
| Other income | ₹2 cr | ₹1 cr | +93.20% | -44.41% |
| Expenses | ₹577 cr | ₹483 cr | +19.47% | +16.27% |
| Operating profit | ₹296 cr | ₹274 cr | +8.28% | +7.05% |
| Operating margin (%) | 33.92% | 36.16% | — | — |
| Interest | ₹47 cr | ₹46 cr | +2.26% | -4.17% |
| Depreciation | ₹72 cr | ₹70 cr | +3.59% | +2.21% |
| Profit before tax | ₹179 cr | ₹159 cr | +12.60% | +11.42% |
| Tax | ₹36 cr | ₹-120 cr | — | +0.47% |
| Net profit | ₹143 cr | ₹279 cr | -48.65% | +14.56% |
| EPS (₹) | ₹10.28 | ₹20.60 | -50.10% | +18.71% |
Operating margin of 33.92% compares with a Healthcare sector median of 29.83% across 11 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Sundae reported its first full quarter with ₹12 crore of sales in a ₹88 crore generic semaglutide market.
Guidance & outlook
- Eris expects its insulin pipeline of five products to start launching from FY28.
- Eris aims to get the OAD segment to 70% of market growth over the next two quarters of FY27.
- Eris aims to retain Sundae's number-one rank in prescription and sale volumes while augmenting value.
Expansion
- Eris plans to get both Swiss Parenterals injectable sites audit ready.
New products
- Eris plans to launch five insulin pipeline products starting in FY28.
New initiatives
- Eris plans to complete CAPA actions for Swiss Parenterals sites.
- Eris's insulin pipeline comprises five products set to launch from FY28.
Competition
- Eris's RHI and Glargine market share increased from 9% to 16% since the Biocon acquisition.
- Sundae led the generic semaglutide market in prescription and sale-unit share in June 2026.
Problems & risks
- The represented RHI and Glargine insulin market segment is declining 1.2% year on year.
What to watch
- Whether operating margin holds above 33.92% after the 2.24-percentage-point QoQ decline.
- Progress in the OAD segment against management's stated aim of reaching 70% of market growth over the next two quarters of FY27.
- Execution on the five-product insulin pipeline that management said is scheduled to begin launching from FY28.